10:03 AM EST - Stem Cell Therapeutics Corp. : announced it will be providing an update on its immune checkpoint program targeting the CD47 protein at the 55th Annual Meeting of the American Society of Hematology, December 7-10, in New Orleans. Stem Cell Therapeutics Corp.
shares V.SSS are trading up $0.01 at $0.28.
